Aurobindo Pharma declares Q3FY22 result: Revenue from Operations at INR 6,002 Cr decreased by 1% over the corresponding period last year US formulations revenue declined by 13.4% on a YoY basis to INR 2,745.2 Cr Europe formulation revenue stood at INR 1,694 Cr, an increase of 1.4% over corresponding previous quarter Growth Markets grew by 2.8% QoQ to INR 397 Cr ARV revenue improved by 7.4% QoQ to INR 156 Cr API revenue for the quarter was at INR 1,010 Cr vs. INR 682.5 Cr in the corresponding previous period EBIDTA before Forex and Other income stood at INR 1,016.3 Cr; EBITDA margin for the quarter was 16.9% Research & Development (R&D;) spend at INR 393 Cr, 6.6% of revenues (Q2 FY22: 6.7%) Received final approval for 4 ANDAs including 1 injectable product from the USFDA Net Profit stood at INR 604.3 Cr as against INR 777.3 Cr in the corresponding previous period Basic & Diluted EPS is INR 10.32 per share Commenting on the Company’s performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “The quarter’s performance was impacted by high input and freight costs, that weighed on profitability. However, our business was resilient in delivering steady revenues, led by API business benefitting from improved demand for our key products. We made progress in optimizing our working capital during the quarter that has strengthened our balance sheet further. We remain committed to resolve the regulatory issues affecting some of our facilities and are continuing to make steady progress in our complex generic product development plans. As a company, we are focused on executing on our key growth drivers to drive sustained improvement in profitability and enhance stakeholder value.” Result PDF